Twin City Private Wealth LLC Has $571,000 Stock Position in Sanofi (NASDAQ:SNY)

Twin City Private Wealth LLC lifted its holdings in shares of Sanofi (NASDAQ:SNY) by 11.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 11,831 shares of the company’s stock after acquiring an additional 1,189 shares during the period. Twin City Private Wealth LLC’s holdings in Sanofi were worth $571,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of SNY. Raymond James Financial Inc. bought a new stake in Sanofi during the 4th quarter worth $135,933,000. Boston Partners grew its position in shares of Sanofi by 86.4% in the 4th quarter. Boston Partners now owns 5,396,531 shares of the company’s stock valued at $260,607,000 after buying an additional 2,501,073 shares during the last quarter. Magnetar Financial LLC grew its position in shares of Sanofi by 104.3% in the 4th quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock valued at $161,103,000 after buying an additional 1,705,148 shares during the last quarter. DAVENPORT & Co LLC grew its position in shares of Sanofi by 40.7% in the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after buying an additional 664,455 shares during the last quarter. Finally, Thrivent Financial for Lutherans grew its position in shares of Sanofi by 36.0% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,943,761 shares of the company’s stock valued at $93,774,000 after buying an additional 514,542 shares during the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Stock Performance

Shares of Sanofi stock opened at $56.90 on Monday. The company has a market cap of $144.40 billion, a PE ratio of 22.85, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. Sanofi has a 52 week low of $45.22 and a 52 week high of $60.12. The business has a 50 day moving average price of $54.55 and a 200-day moving average price of $52.85. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Equities analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on SNY shares. The Goldman Sachs Group started coverage on Sanofi in a research report on Friday. They issued a “neutral” rating and a $65.00 price target on the stock. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.